Knowledge Library

DEA Extends COVID Telemedicine Prescribing Rules for Controlled Substances

On May 3rd the U.S. Drug Enforcement Administration announced that it had temporarily extended the COVID-19 telemedicine flexibilities for prescribing controlled substances. This decision, which referenced the 38,000 public comments submitted since the proposed telemedicine rules were first announced in February, will allow the DEA to consider further changes to those rules before they are finalized. For details on the proposed DEA rules, please see our article DEA Announces Proposed Telemedicine Rule Change for Controlled Substances. The rules, which had been set to take effect with the expiration of the federal COVID Public Health Emergency (PHE) on May 11th, are...

Read More » Filed under: , , ,

DEA Announces Proposed Telemedicine Rule Change for Controlled Substances

On 2/24/23 the U.S. Drug Enforcement Agency (DEA) announced a proposal for permanent rule changes to the Ryan Haight Act that will allow for the prescription of controlled substances through telemedicine, under certain circumstances, after the federal COVID-19 Public Health Emergency (PHE) expires on May 11, 2023. The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 requires prescribers conduct an in-person examination to evaluate each patient at least once before prescribing a controlled substance, even if a patient has already been taking the medication in question. During the PHE, the in-person requirement was changed to allow prescribers to perform...

Read More » Filed under: , , , , ,

California Providers – Mandatory CURES Reports

As of October 2, 2018, all providers practicing in California must check the Controlled Substance Utilization Review and Evaluation System (CURES) database before prescribing certain medications, including opioid pain medications. Physicians and advanced practice providers who prescribe controlled substances already must be registered with CURES 2.0, according to state law.  California Health and Safety Code Section 11165.1 requires health care practitioners authorized to prescribe, order, administer, furnish, or dispense scheduled controlled substances to submit a CURES registration application to the Department of Justice before July 1, 2016, or upon receipt of a DEA registration. Senate Bill 482, which was signed...

Read More » Filed under: , , , , ,

Hawai’i Providers: Mandatory Opioid Prescription Requirements under Act 66

MIEC’s member providers in Hawai'i who prescribe opioid pain medications should be aware of a new state law which just went into effect this month. This new law imposes more stringent requirements around chronic pain management, patients who are also taking anti-anxiety medication, and/or patient who are on large dosages of opioids. Specific elements of the law are discussed below. Under Hawai'i Act 66 (17), Relating to Heath, as of July 1, 2018, all providers authorized to prescribe opioids in Hawai'i must adopt a written policy that includes the execution of a written informed consent document when prescribing opioids to...

Read More » Filed under: , , , , ,